WallStSmart

Boston Scientific Corp (BSX)vsSight Sciences Inc (SGHT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 25848% more annual revenue ($20.07B vs $77.36M). BSX leads profitability with a 14.4% profit margin vs -49.7%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

SGHT

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.72
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for SGHT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

SGHT0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

SGHT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$187.40M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-50.7%2/10

ROE of -50.7% — below average capital efficiency

Free Cash FlowQuality
$-1.98M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : SGHT

SGHT has a balanced fundamental profile.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : SGHT

The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while SGHT is a turnaround play — different risk/reward profiles.

SGHT carries more volatility with a beta of 2.43 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 29/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Sight Sciences Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sight Sciences Inc. (SGHT) is a pioneering medical technology company focused on transforming the management of eye diseases through innovative surgical and non-surgical solutions, particularly targeting glaucoma care. With a robust portfolio of cutting-edge products and a strong intellectual property foundation, the company is strategically positioned to capitalize on the increasing demand for minimally invasive therapies in the ophthalmology sector. As Sight Sciences expands its distribution network and continues to drive advancements in eye care, it presents a compelling investment opportunity for institutional investors looking to engage with the dynamic healthcare market.

Want to dig deeper into these stocks?